Opinion
Video
Author(s):
Faculty review the objectives of the 2023 ASH Insights Program on the Efficacy and Safety of Brexucabtagene Autoleucel CART19 Cell Therapy in Adults with Advanced Acute Lymphoblastic Leukemia.
Iopofosine I 131 Meets MRR End Point in R/R Waldenström Macroglobulinemia
Revisit the OncLive On Air Episodes From February 2024
Five-Year Follow-Up Data Confirm Long-Term Benefits of Olutasidenib in R/R IDH1+ AML
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
Brentuximab Vedotin Triplet Improves Survival Over R2 Across Key R/R DLBCL Subgroups
FDA Grants Priority Review to Tabelecleucel for Adult/Pediatric EBV+ Post-Transplant Lymphoproliferative Disease
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC
Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer
Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium